Targeted Oncology
@targetedonc
Oncology news and insights from leading researchers and cancer centers.
ID: 726304448
http://targetedonc.com 30-07-2012 15:43:54
43,43K Tweet
20,20K Takipçi
3,3K Takip Edilen
The MARIPOSA trial of amivantamab + lazertinib vs standard-of-care osimertinib for the treatment of EGFR-mutated #NSCLC had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. Alex Spira, M.D. Virginia Cancer Specialists targetedonc.com/view/amivantam…